Core Insights - Coherus Oncology is transitioning into an innovative oncology company focused on overcoming immune resistance in cancer, with a strong emphasis on its commercial PD-1 therapy LOQTORZI and new pipeline assets acquired from Surface Oncology [5][22]. Group 1: LOQTORZI Overview - LOQTORZI is described as a next-generation PD-1 therapy with high-affinity binding, effective in low PD-L1 cancers, and is currently labeled for low PD-L1 esophageal cancer in the EU [1]. - Sales of LOQTORZI increased significantly from $19.1 million in 2024 to $40.8 million in 2025, with expectations of reaching $15–16 million per quarter in 2026 and targeting a 70% market share by 2028, equating to approximately $175 million annualized [7][10]. - The company is pursuing a $33 billion opportunity based on ongoing trials in the U.S. [2]. Group 2: Financial Developments - Coherus completed the sale of UDENYCA to Intas for an upfront payment of $483 million, with additional payments expected, which will support the company's financial stability [3]. - The company has paid down nearly $480 million in debt and retained $250 million on its balance sheet to fund development efforts [4][7]. Group 3: Pipeline Progress - The pipeline includes tagmokitug, a CCR8 Treg depleter, and casdozokitug, an IL-27 blocker, with promising clinical outcomes reported, including a 38% overall response rate in first-line hepatocellular carcinoma [6][17]. - Tagmokitug is being studied in various cancers, including head and neck and gastrointestinal cancers, and is expected to enter prostate cancer studies in collaboration with Johnson & Johnson [12][15]. - Coherus is also exploring additional collaborations for tagmokitug and casdozokitug, aiming for ex-U.S. licensing to manage development costs [21].

Financial Data and Key Metrics Changes - The company reported a net income of $3.8 million for Q4 2025, translating to $0.06 per share, while the full-year net loss was $84.9 million or $1.81 per share [25][26] - Total operating expenses decreased from $112.6 million in 2024 to $86.9 million in 2025, marking a 23% reduction [25] - Cash equivalents and short-term investments decreased from $94.1 million at the end of 2024 to $58.5 million at the end of Q4 2025 [25] Business Line Data and Key Metrics Changes - The primary focus remains on advancing INO-3107 towards FDA approval, with significant resources allocated to this lead candidate [5][24] - The company has also advanced its DNA medicine platform, including promising phase 1 proof of concept data for dMAb technology [21] Market Data and Key Metrics Changes - The market for recurrent respiratory papillomatosis (RRP) treatment is characterized by a significant burden on patients, with many requiring numerous surgeries throughout their lives [15] - Market research indicates that INO-3107 could become the preferred treatment option based on its efficacy and tolerability [16] Company Strategy and Development Direction - The company is focused on optimizing resources to extend its cash runway towards the October 30, 2026 PDUFA date for INO-3107 [24][60] - Strategic partnerships are being leveraged to advance other promising candidates in the pipeline, including collaborations in glioblastoma research [8][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in INO-3107's ability to meet an unmet medical need and provide a meaningful therapeutic benefit over existing treatments [7][11] - The company is preparing for a meeting with the FDA to discuss the BLA for INO-3107 and is awaiting feedback on an updated protocol for a confirmatory trial [10][30] Other Important Information - The company has reduced headcount by approximately 15% to conserve financial resources [24] - The FDA has accepted the BLA for INO-3107 under the Accelerated Approval Program, with a standard review timeline of 10 months [5][9] Q&A Session Summary Question: Additional data needed for FDA conversations regarding accelerated approval - Management confirmed that no new clinical data is required, but they have submitted new documentation to the FDA [30] Question: Impact of a potential priority review on launch preparations - The focus is currently on ensuring alignment with the FDA for accelerated approval, with commercial preparations well advanced [34][35] Question: Feedback from KOLs and patients on recent publications - Research indicates a strong preference for INO-3107 based on its efficacy and tolerability, with significant reductions in surgeries reported by patients [37][38] Question: Incorporating learnings from competitor's rollout into distribution strategy - The company is learning from competitor experiences and ensuring that their distribution strategy is well-prepared for launch [42][44] Question: Biological rationale of the dual PD-1/CTLA-4 blockade in partnership with Akeso - The combination aims to enhance immune responses against tumor-associated antigens, building on previous encouraging data [48][49] Question: Plans for INO-3112 if INO-3107 is approved - The company plans to focus resources on INO-3107 first, with potential to advance INO-3112 following approval and available financial resources [55]

Financial Data and Key Metrics Changes - Coherus Oncology reported a net revenue of $40.8 million for the full year 2025, representing a 113% growth year-over-year compared to $19.1 million in 2024 [28] - For Q4 2025, net revenue was $12.4 million, reflecting an 11% growth over Q3 2025, with a strong quarter-over-quarter demand growth of 15.5% in Q4 [28] - The company reduced its secured and convertible debt by over 90% from $480 million to $38.8 million by the end of 2025, significantly lowering interest costs [34][38] Business Line Data and Key Metrics Changes - LOQTORZI, the company's first innovative oncology commercial product, more than doubled its sales in 2025 compared to 2024, with expectations of continued growth driven by new patient starts and increased market penetration [6][28] - The company anticipates achieving peak market share for LOQTORZI by 2028, targeting $175 million in annualized revenues, which would represent about 70% market share of the $250 million total addressable market [7][32] Market Data and Key Metrics Changes - The NCCN guidelines for nasopharyngeal carcinoma (NPC) were updated in late 2024, positioning LOQTORZI as the only preferred treatment for recurrent and metastatic NPC, which has stimulated growth in 2025 [29] - The company is focusing on expanding its reach in the community segment, where off-label immuno-oncology (IO) treatments persist [29] Company Strategy and Development Direction - Coherus has transitioned from a biosimilar company to an innovative oncology company, focusing on overcoming immune resistance in cancer through strategic acquisitions and product development [4][6] - The company is investing in its pipeline, particularly in tagmokitug and Casdozokitug, with multiple clinical readouts expected in 2026 [10][27] - The strategic partnership with Johnson & Johnson for tagmokitug is seen as a validation of the company's scientific competency and a pathway to further collaborations [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LOQTORZI's growth trajectory, supported by strong clinical data showing significant survival benefits compared to chemotherapy alone [30] - The company is well-positioned financially, with sufficient funding to support operations and pipeline advancements through 2026 and into 2027 [9][39] - Management highlighted the importance of educating oncologists on the new survival data to drive adoption of LOQTORZI [30] Other Important Information - The company has reduced its headcount from approximately 228 at the end of 2024 to about 147 at the end of 2025, reflecting a 35% reduction [34] - Coherus is eligible for two earn-out sales milestones of $37.5 million each based on UDENYCA sales performance, which could provide additional financial support [36] Q&A Session Summary Question: Can you provide more color on the dynamic between new patient starts and repeat patients in 2025? - Approximately 25% of the business came from new patients in 2025, with expectations that this mix will shift slightly more towards new patients in 2026 as the duration of therapy for existing patients increases [46] Question: What are the promotional sensitivities of LOQTORZI? - LOQTORZI is highly promotion sensitive, requiring continuous reminders to physicians about its benefits due to the rarity of NPC cases [49] Question: Can you discuss the additional investments in commercial infrastructure? - The company has expanded its field force by 15% and added inside sales representatives to target tier 2 accounts, along with investments in IT infrastructure to capture patient opportunities [51][52] Question: What are the plans for exploring a triple combination with TAGMO? - The initial step will be to evaluate the combination of tagmokitug and pasritamig before considering additional combinations [57] Question: How will data from ongoing trials be disclosed? - Data will be reported as it becomes available, either aligned with congress submission deadlines or through corporate disclosures [62]

Financial Data and Key Metrics Changes - Coherus Oncology reported a net revenue of $40.8 million for the full year 2025, representing a 113% increase from $19.1 million in 2024 [35] - The company reduced its secured and convertible debt by over 90% from $480 million to $38.8 million by the end of 2025 [4][41] - SG&A expenses decreased to $23.6 million in Q4 2025 from $29.6 million in Q4 2024, marking the fourth consecutive quarter of flat or declining expenses [44] - R&D expenses increased to $31 million in Q4 2025 compared to $20.8 million in Q4 2024, reflecting ongoing investments in the pipeline [44] Business Line Data and Key Metrics Changes - LOQTORZI, the company's first innovative oncology product, saw its sales more than double in 2025 compared to 2024 [6][49] - For Q4 2025, LOQTORZI net revenue was $12.4 million, an 11% growth over Q3 2025, driven by a 15.5% increase in demand [35] - The company anticipates achieving peak market share of approximately 70% in the nasopharyngeal carcinoma (NPC) market by 2028, equating to $175 million in annualized revenues [7][40] Market Data and Key Metrics Changes - The NCCN guidelines for NPC were updated in late 2024, positioning LOQTORZI as the only preferred treatment for recurrent and metastatic NPC, which stimulated growth in 2025 [36] - The addressable market for LOQTORZI is estimated at $250 million, with significant opportunities remaining, particularly in the community segment [35][36] Company Strategy and Development Direction - Coherus has transitioned to focus on innovative oncology, particularly in overcoming immune resistance in cancer, following the acquisition of Surface Oncology [4] - The company aims to leverage LOQTORZI as a revenue generator while advancing its pipeline, including tagmokitug and Casdozokitug, which are positioned for broad clinical utility [6][10] - Strategic partnerships, such as the collaboration with Johnson & Johnson, are seen as key to expanding market reach and enhancing the value of the pipeline [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LOQTORZI's growth trajectory, supported by strong clinical data showing significant survival benefits over chemotherapy alone [37] - The company is well-funded through 2026 and into 2027, allowing for continued investment in its promising pipeline and commercial efforts [9][41] - Management highlighted the importance of educating oncologists on the new survival data to drive adoption of LOQTORZI [38][39] Other Important Information - The company has reduced its headcount from approximately 228 at the end of 2024 to about 147 at the end of 2025, a reduction of about 35% [41] - Coherus is eligible for two earn-out sales milestones of $37.5 million each based on UDENYCA sales, which could provide additional financial support [43] Q&A Session Summary Question: Can you provide more color on the dynamic between new patient starts and repeat patients in 2025? - In 2025, approximately 25% of business came from new patients, with the expectation that this mix will shift slightly more towards new patients in the future [51][53] Question: What is the promotional sensitivity of LOQTORZI? - LOQTORZI is highly promotion sensitive, requiring continuous reminders to physicians about its benefits due to the rarity of NPC cases [57] Question: What are the plans for exploring a triple combination with Tagmo? - The initial step will be to evaluate the combination of Tagmo and pasritamig before considering additional combinations [64] Question: How will data from ongoing trials be disclosed? - Data will be reported as it matures, either at congresses or through corporate disclosures, depending on the timing of patient accrual and scans [70] Question: What are the important updates on the competitive front for CCR8 this year? - The company anticipates more data disclosures from competitors, which could impact development strategies [80]

Financial Data and Key Metrics Changes - Coherus Oncology reported LOQTORZI net revenue of $40.8 million for the full year 2025, a 113% increase from $19.1 million in 2024 [27] - The company reduced its secured and convertible debt by over 90% from $480 million to $38.8 million by the end of 2025 [3][32] - SG&A expenses decreased to $23.6 million in Q4 2025 from $29.6 million in Q4 2024, marking the fourth consecutive quarter of flat or declining expenses [36] Business Line Data and Key Metrics Changes - LOQTORZI sales more than doubled in 2025 compared to 2024, with Q4 net revenue reaching $12.4 million, an 11% growth over Q3 [27][31] - The company launched LOQTORZI in 2024, targeting a $250 million addressable market for recurrent, locally advanced, or metastatic Nasopharyngeal Carcinoma [4] Market Data and Key Metrics Changes - The NCCN guidelines for NPC were updated in late 2024, positioning LOQTORZI as the only preferred treatment for recurrent and metastatic NPC, which stimulated growth in 2025 [28] - The company anticipates achieving peak market share of approximately 70% in the NPC market by 2028, equating to $175 million in annualized revenues [6][31] Company Strategy and Development Direction - Coherus has transitioned to focus on innovative oncology, particularly in overcoming immune resistance in cancer, following the acquisition of Surface Oncology [3] - The company aims to leverage LOQTORZI as a revenue generator while advancing its pipeline products, including tagmokitug and Casdozokitug, which are positioned for broad clinical utility [5][9] - Strategic partnerships, such as the collaboration with Johnson & Johnson, are seen as key to unlocking value and expanding market opportunities [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LOQTORZI's growth due to its unique position in the market and the compelling survival data presented at ESMO Asia [29] - The company is focused on educating oncologists about the benefits of LOQTORZI, particularly in light of new survival data that shows significant advantages over chemotherapy alone [30] - Management believes that the financial strategy, including reduced debt and growing revenues, positions the company well for future growth [40] Other Important Information - The company has made significant investments in commercial infrastructure to support LOQTORZI's growth, including expanding its sales force and enhancing data analytics capabilities [30] - Coherus is on track for initial data readouts from its clinical programs in mid-2026, which will inform future development strategies [18][26] Q&A Session Summary Question: Can you provide more color on the dynamic between new patient starts and repeat patients in 2025? - Approximately 25% of the business came from new patients in 2025, with expectations that this mix will shift slightly more towards new patients in the future [45] Question: What is the promotional sensitivity of LOQTORZI? - LOQTORZI is highly promotion sensitive, requiring continuous reminders to physicians about its benefits due to the rarity of NPC cases [48] Question: Can you discuss the additional investments in commercial infrastructure? - The company has expanded its field force by 15% and added inside sales representatives to target tier 2 accounts, along with investments in IT infrastructure to capture patient opportunities [49][50] Question: What are the plans for exploring a triple combination with TAGMO? - The initial step will be to evaluate the combination of tagmokitug and pasritamig before considering additional combinations [55] Question: How will data from ongoing trials be disclosed? - Data will be reported as it matures, either at congresses or through corporate disclosures, depending on the timing of patient accrual and scans [61] Question: What is the maturation timeline for the Casdozokitug frontline HCC study? - The maturation timeline is expected to be between 6 to 12 months, with ongoing data collection to inform future reports [68]

Core Insights - Coherus is launching LOQTORZI for nasopharyngeal carcinoma (NPC), addressing an unmet medical need with an estimated 2,000 patients annually who previously relied on chemotherapy or off-label immuno-oncology treatments [1] - The company has undergone a significant transformation, enhancing its team, board, and investor base, and has recently completed a financing round, resulting in a strong balance sheet with cash reserves [2] - Coherus has reduced its debt by approximately 90%, from about $480 million to $3.7 million, and added $250 million to its balance sheet, which supports its oncology pipeline development [3][7] Commercial Launch and Financial Performance - LOQTORZI's commercialization is accelerating, generating about $19 million in sales in 2024, with sales doubling in 2025, and the company expects to reach a self-funding status at approximately $15-16 million per quarter by 2026 [6][8] - Management targets a run rate of roughly $175 million per year by 2028, representing about 70% penetration of a $250 million market opportunity [17] - LOQTORZI has shown a significant overall survival benefit of 65 months compared to 34 months with chemotherapy alone, and it is listed as the only "preferred" option in the NCCN guidelines for NPC [9] Pipeline Developments - Coherus is advancing its pipeline with tagmokitug (anti-CCR8) showing selective tumor Treg depletion of 52-97% without dose-limiting toxicities, and casdozokitug (anti-IL-27) demonstrating liver/lung-specific activity [5][16] - A randomized phase II readout for casdozokitug is expected in mid-2026, with ongoing studies showing improved response rates in liver cancer when combined with standard therapies [19][20] - The company is pursuing partnerships to share costs in pivotal trials for its pipeline assets, including collaborations with Johnson & Johnson [14][15] Strategic Focus - Coherus is focused on three main priorities: enhancing the commercial launch of LOQTORZI, advancing its pipeline assets, and implementing a financial strategy to reduce development costs while maximizing shareholder value [21]

Coherus Oncology FY Conference Summary Company Overview - **Company**: Coherus Oncology (NasdaqGM:CHRS) - **Date of Conference**: March 04, 2026 - **Focus**: Transformation into an innovative oncology company, with significant debt reduction and product development initiatives Key Metrics and Financials - **Debt Reduction**: Reduced indebtedness by 90%, from approximately $480 million to $3.7 million in senior secured debt [2][6] - **Cash Position**: Strong balance sheet with $172 million at the end of Q4, further improved with recent financing [9] - **Sales Growth**: Sales of LOQTORZI increased from $19 million in 2024 to approximately $38 million in 2025, with expectations for continued growth in 2026 [5][10] Product Development and Pipeline LOQTORZI - **Indication**: Nasopharyngeal carcinoma (NPC) with a significant unmet need; launched in 2024 [7] - **Market Opportunity**: Estimated market size of $250 million, with a target of achieving $175 million in annual sales by 2028 [11] - **Sales Strategy**: Enhanced commercial team and sophisticated data acquisition tools to identify and reach patients [8][9] - **Clinical Data**: Demonstrated overall survival benefit of 65 months with LOQTORZI compared to 34 months with chemotherapy alone [4] Tagmokitug (Anti-CCR8 Antibody) - **Mechanism**: Targets T-regulatory cells (Tregs) selectively, showing 52%-97% depletion in tumors without affecting CD4s and CD8s [15][16] - **Tumor Types**: High potential across various solid tumors including head and neck, gastrointestinal, and breast cancers [17] - **Clinical Development**: Ongoing studies to optimize dosing and understand the best contexts for treatment [18][19] - **Partnerships**: Interest from larger companies for collaborations, particularly in combination therapies [23][24] Casdozokitug (Anti-IL-27) - **Mechanism**: Inhibits IL-27 to activate T cells and NK cells, showing promising results in liver and lung cancers [36][39] - **Clinical Data**: Achieved a 17% complete response rate in liver cancer, significantly higher than the previous highest of 8% [41] - **Ongoing Studies**: Randomized phase 2 study with initial readout expected mid-year 2026 [43] Strategic Insights - **Transformation Strategy**: Focus on product, clinical, and financial strategies to enhance investor value [52] - **Market Positioning**: Coherus aims to leverage its unique product offerings and partnerships to address significant gaps in oncology treatment [24][25] - **Future Outlook**: Anticipation of strong data readouts and continued growth in sales and clinical advancements [53] Additional Considerations - **Collaborative Opportunities**: Open to various licensing and partnership arrangements to reduce clinical trial costs and enhance development capabilities [25] - **Biomarker Strategy**: Potential to develop a biomarker strategy based on CCRA presence in tumors to enrich patient populations [32] This summary encapsulates the key points discussed during the Coherus Oncology FY Conference, highlighting the company's strategic direction, product pipeline, and financial health.

Core Insights - The company is focused on transforming into an innovative oncology firm that aims to overcome immune resistance in cancer treatment [3] Company Progress - The CEO provided an update on the company's progress over the past 12 months since the last conference [2] - The cornerstone therapy for the company is LOQTORZI, which serves as a revenue multiplier in conjunction with their PD-1 backbone [3] Promising Assets - The company is developing Tagmokitug, a promising asset in the evolving class of Treg depleters, highlighting its mechanism of action and potential as a new treatment paradigm [3] - Casdozokitug was also mentioned as part of the company's portfolio, indicating ongoing development in innovative cancer therapies [3]

Coherus Oncology Conference Summary Company Overview - **Company**: Coherus Oncology (NasdaqGM:CHRS) - **Focus**: Transitioned from a biosimilar company to a commercial-stage innovative oncology company with a focus on immuno-oncology pipeline, particularly PD-1 inhibitors and novel therapies [3][4][5] Key Products and Pipeline - **Toripalimab**: FDA-approved next-generation PD-1 inhibitor, cornerstone of the oncology pipeline [4][5] - **Casdozokitug**: First-in-class anti-IL27 therapy showing promise in liver cancer and other tumor types [11][12] - **Tagmukitug**: Cytolytic antibody targeting CCR8, showing potential in various solid tumors [53][54] Clinical Data and Efficacy - **Casdozokitug**: - Phase 1 trial showed manageable safety profile with no dose-limiting toxicities (DLTs) [16] - Monotherapy activity observed in squamous non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) [17] - In combination with Atizo and Bev for hepatocellular carcinoma (HCC), showed an overall response rate (ORR) of 38% and a complete response (CR) rate of 17%, compared to historical controls of 30% and 8% respectively [20][21] - Responses observed irrespective of viral etiology, indicating broad applicability [22] - **Tagmukitug**: - Demonstrated ability to deplete CCR8-positive T regulatory cells in tumors, leading to increased CD8 T cell activity [56] - Early data from head and neck cancer patients showed promising responses in heavily pre-treated individuals [62] Safety and Tolerability - **Casdozokitug**: Safety profile encouraging, with no significant increase in immune-related adverse events compared to standard treatments [26][27] - **Tagmukitug**: Selective targeting of CCR8 with a favorable safety profile, avoiding off-target toxicity seen in other CCR8 programs [58][59] Market Position and Future Outlook - **Market Strategy**: Coherus aims to leverage its innovative pipeline to establish a strong position in the oncology market, focusing on underserved patient populations [5][9] - **Upcoming Milestones**: - Initial data for the Casdozokitug triplet combination expected in mid-2026 [47] - Continued development of Tagmukitug across multiple tumor types with data anticipated throughout 2026 [65] Conclusion - Coherus Oncology is positioned for a data-rich 2026 with promising clinical trials and innovative therapies that could significantly impact cancer treatment, particularly in HCC and other solid tumors [71]

Coherus Oncology Conference Call Summary Company Overview - **Company**: Coherus Oncology - **Ticker**: NasdaqGM:CHRS - **Industry**: Oncology Key Points Company Value Proposition - Coherus Oncology's value proposition is summarized as "drugs, data, and deals" [2][28] - The company focuses on innovative oncology treatments, particularly in the PD-1 space with LOQTORZI and emerging therapies like CHS-114 and casdozokitug [2][3] Product Pipeline - **LOQTORZI**: A foundational PD-1 product approved for nasopharyngeal cancer, expected to generate revenue and expand its label with ongoing studies [4][6] - **CHS-114**: A highly selective Treg depleter, recognized as an important therapeutic approach, with studies in colorectal and gastric cancers [3][4][19] - **Casdozokitug**: An anti-IL-27 therapy being developed for liver and lung cancers, showing promising early data [3][21] Market Potential - The combined pipeline addresses a market opportunity of approximately **$30 billion** in the U.S. across multiple cancer indications [6] - LOQTORZI is projected to reach a revenue range of **$150-$200 million** by mid-2028, with a growth rate of **10%-15%** in recent quarters [9][10] Clinical Studies and Data - Ongoing studies for CHS-114 in colorectal and gastric cancers, with data expected in **2026** [5][19] - Casdozokitug has shown a **60%** tumor shrinkage rate and a **38%** overall response rate in initial studies, significantly outperforming standard care [24] Strategic Partnerships and Licensing - Coherus has a strong track record of divesting biosimilar assets, raising nearly **$800 million** and paying off **$480 million** in debt [25][26] - The company is focused on collaborations to enhance patient survival through combination therapies, leveraging its PD-1 and other products with partners [26][27] Scientific Innovations - LOQTORZI's mechanism involves high-affinity binding at the FG loop, leading to significant T cell signaling advantages [8] - CHS-114 targets CCR8 on Treg cells in the tumor microenvironment, aiming to enhance immune response against tumors [11][14] Future Outlook - Coherus is optimistic about the outcomes of ongoing studies and the potential for expanding its pipeline into additional cancer types [20][28] - The company is actively seeking to validate its pipeline through partnerships and collaborations, which will also help offset clinical trial costs [27][28] Additional Insights - The company emphasizes the importance of Treg depletion in treating "cold" tumors, which represent **70%** of certain cancer types [12][19] - The strategic acquisition of Surface Oncology for **$65 million** has positioned Coherus for innovative oncology advancements [26] This summary encapsulates the key insights from the Coherus Oncology conference call, highlighting the company's strategic direction, product pipeline, market potential, and scientific innovations.